DEF: bioAffinity Seeks Shareholder Approval for Major Dilution

bioAffinity Technologies calls a Special Meeting to approve significant share issuances, anti-dilution adjustments, and a large equity plan increase, signaling substantial future dilution.

Summary

• A Special Meeting of Stockholders is scheduled for December 19, 2025, to vote on seven proposals related to capital structure and equity compensation.
• Shareholders are asked to approve the issuance of up to 271,500 shares of Common Stock from August 2025 Warrants, which could generate approximately $2.9 million in gross proceeds if exercised for cash at $10.56 per share.
• Approval is sought for anti-dilution provisions for August 2025 Warrants, potentially increasing shares issuable by up to 365,620 (with a floor price of $4.50 per share) if a dilutive issuance occurs.
• Approval is also sought for anti-dilution provisions for Series B Convertible Preferred Stock, potentially increasing shares issuable by up to 131,884 (with a floor price of $3.00 per share) if a dilutive issuance occurs.
• The company proposes to amend its 2024 Equity Incentive Plan, increasing the shares reserved for issuance from 66,666 to 750,000, representing approximately 20% of current fully diluted Common Stock.
• Authorization is requested to issue up to 10 million shares of Common Stock in one or more non-public offerings, aiming to raise up to $10 million in cash, with a potential discount of up to 35% below market price, by December 31, 2026.
• The Board unanimously recommends a 'FOR' vote on all seven proposals, including an adjournment proposal if insufficient votes are received.

Sentiment

Score: 3

Explanation: The filing outlines necessary steps for the company's continued operation and growth, such as securing funding and incentivizing employees. However, the sheer scale of potential dilution from warrant exercises, anti-dilution adjustments, an expanded equity plan, and future offerings (totaling potentially over 11 million shares against 3.6 million currently outstanding) is a significant negative. The fact that the current stock price is well below the warrant exercise prices suggests financial distress and a high likelihood of anti-dilution triggers, further exacerbating dilution. This indicates a challenging financial position for existing shareholders.

Positives

• Approval of the Warrant Exercise Proposal could provide up to $2.9 million in gross proceeds, supporting company operations.
• Increasing the 2024 Equity Incentive Plan shares to 750,000 aims to attract, motivate, and retain highly qualified talent, aligning their interests with stockholders.
• Authorization for future non-public offerings provides flexibility to raise up to $10 million for general corporate purposes and strategic M&A initiatives.

Negatives

• All proposals, if approved, will result in significant dilution of existing stockholders' ownership interests.
• The potential issuance of up to 10 million shares in future non-public offerings represents a massive dilution relative to the 3,633,815 shares currently outstanding.
• Future offerings may occur at a discount of up to 35% below market price, further impacting shareholder value.
• The current closing price of Common Stock ($2.90 on November 4, 2025) is significantly below the initial exercise prices of the August 2025 Warrants ($10.56) and Series B Preferred Stock conversion price ($6.90), indicating that anti-dilution provisions are likely to be triggered, leading to more shares issued for the same or less capital.
• Failure to approve anti-dilution proposals would incur substantial additional costs and require the company to hold meetings every three months until approval is obtained or warrants/preferred stock are no longer outstanding.

Risks

• Existing stockholders will suffer significant dilution in their ownership interests upon the issuance of shares from warrant exercises, anti-dilution adjustments, equity incentive plan awards, and future non-public offerings.
• The sale of newly issued shares into the public market could materially and adversely affect the market price of the Common Stock.
• Concentration of voting power in the hands of a few stockholders could occur if one or more investors acquire a large block of shares in a non-public offering, potentially influencing company operations or voting outcomes.
• Failure to obtain stockholder approval for warrant exercises and anti-dilution adjustments could adversely impact the company's ability to fund operations and incur substantial additional costs and expenses.

Future Outlook

The company aims to continue developing noninvasive diagnostics for lung cancer and other lung diseases, driven by a mission to increase early-stage cancer detection. It anticipates the additional shares requested under the 2024 Equity Incentive Plan to be sufficient for two years. The company may seek to raise additional capital through non-public offerings by December 31, 2026, to implement its business strategy and enhance overall capitalization, including strategic M&A initiatives.

Management Comments

• President and CEO Maria Zannes is 'greatly encouraged by the growing adoption and use by physicians of our first test, CyPath Lung, a noninvasive test for lung cancer, and of the technological advancements that our team continues to make in its fight to address the urgent need for noninvasive, early-stage diagnosis.'
• Management emphasizes, 'Your trust in our team and belief in our technology are invaluable.'
• The Board of Directors, executive leadership team, and dedicated team extend 'sincerest gratitude for your continued support of and investment in bioAffinity Technologies.'

Industry Context

bioAffinity Technologies operates in the noninvasive diagnostics sector, specifically targeting lung cancer and other lung diseases. The company highlights an 'urgent need for noninvasive, early-stage diagnosis' in this field. The competitive business environment for talent is also noted, underscoring the importance of equity-based compensation to attract and retain key personnel.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience significant dilution of their ownership interests due to the issuance of shares from warrant exercises, anti-dilution adjustments, equity incentive plan awards, and potential future non-public offerings. The market price of Common Stock could be adversely affected.
• Employees, Officers, Directors, and Consultants: Will benefit from increased equity-based compensation opportunities under the expanded 2024 Equity Incentive Plan, aligning their interests with the company's success and aiding in talent attraction and retention.
• Investors (new): Those participating in future non-public offerings may acquire shares at a discount, potentially gaining significant voting power if large blocks are purchased.
• Company Operations: Potential proceeds from warrant exercises and future offerings will provide capital to fund operations, implement business strategy, and pursue strategic M&A initiatives.

Next Steps

• Stockholders to vote on seven proposals at the Special Meeting on December 19, 2025.
• If approved, the company will be able to permit the exercise of August 2025 Warrants, potentially realizing up to $2.9 million in proceeds.
• If approved, the company will be able to implement anti-dilution adjustments for warrants and Series B Preferred Stock if dilutive issuances occur.
• If approved, the company will have 750,000 shares reserved for its 2024 Equity Incentive Plan.
• If approved, the company will be authorized to conduct one or more non-public offerings to raise up to $10 million by December 31, 2026.
• The company will continue its mission to develop noninvasive diagnostics for lung cancer and other lung diseases.

Key Dates

Recommendation

The filing reveals a company in significant need of capital, proposing measures that will lead to massive dilution for existing shareholders. The aggregate potential dilution from warrant exercises, anti-dilution provisions, an expanded equity plan, and future offerings could exceed 11 million shares, compared to the current 3.6 million shares outstanding. The current stock price being substantially below warrant exercise prices indicates that anti-dilution triggers are highly probable, further increasing dilution. Authorizing future capital raises at discounts of up to 35% signals a willingness to heavily dilute to secure funding. This level of dilution and implied financial pressure presents a severe risk to existing shareholder value, making a 'strong sell' recommendation appropriate for a seasoned investor.

Keywords

bioAffinity Technologies, BIAF, SEC filing, Proxy Statement, Special Meeting, Stockholder Approval, Warrants, Anti-Dilution, Equity Incentive Plan, Capital Raise, Dilution, Nasdaq Listing Rules, Lung Cancer Diagnostics, Private Placement